Lim, Ho YeongHo YeongLimMerle, PhilippePhilippeMerleWeiss, Karl HeinzKarl HeinzWeissYau, ThomasThomasYauRoss, PaulPaulRossMazzaferro, VincenzoVincenzoMazzaferroBlanc, Jean-FrédéricJean-FrédéricBlancMa, Yuk TingYuk TingMaYen, Chia JuiChia JuiYenKocsis, JuditJuditKocsisChoo, Su PinSu PinChooSukeepaisarnjaroen, WattanaWattanaSukeepaisarnjaroenGérolami, RenéRenéGérolamiDufour, Jean-FrançoisJean-FrançoisDufourGane, Edward JEdward JGaneRyoo, Baek-YeolBaek-YeolRyooPeck-Radosavljevic, MarkusMarkusPeck-RadosavljevicDao, ThongThongDaoYeo, WinnieWinnieYeoLamlertthon, WisutWisutLamlertthonThongsawat, SatawatSatawatThongsawatTeufel, MichaelMichaelTeufelRoth, KatrinKatrinRothReis, DiegoDiegoReisChilds, Barrett HBarrett HChildsKrissel, HeikoHeikoKrisselLlovet, Josep MJosep MLlovet2024-10-072024-10-072018-10-01https://boris-portal.unibe.ch/handle/20.500.12422/59871Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in combination with sorafenib in patients with -mutated hepatocellular carcinoma (HCC). Two phase II studies evaluated the efficacy of refametinib monotherapy and refametinib plus sorafenib in patients with -mutant unresectable or metastatic HCC. Eligible patients with mutations of cell-free circulating tumor DNA (ctDNA) determined by beads, emulsion, amplification, and magnetics technology received twice-daily refametinib 50 mg ± sorafenib 400 mg. Potential biomarkers were assessed in ctDNA via next-generation sequencing (NGS). Of 1,318 patients screened, 59 (4.4%) had a mutation, of whom 16 received refametinib and 16 received refametinib plus sorafenib. With refametinib monotherapy, the objective response rate (ORR) was 0%, the disease control rate (DCR) was 56.3%, overall survival (OS) was 5.8 months, and progression-free survival (PFS) was 1.9 months. With refametinib plus sorafenib, the ORR was 6.3%, the DCR was 43.8%, OS was 12.7 months, and PFS was 1.5 months. In both studies, time to progression was 2.8 months. Treatment-emergent toxicities included fatigue, hypertension, and acneiform rash. Twenty-seven patients had ctDNA samples available for NGS. The most frequently detected mutations were in (63.0%), (48.1%), and β-catenin (; 37.0%). Prospective testing for family mutations using ctDNA was a feasible, noninvasive approach for large-scale mutational testing in patients with HCC. A median OS of 12.7 months with refametinib plus sorafenib in this small population of -mutant patients may indicate a synergistic effect between sorafenib and refametinib-this preliminary finding should be further explored.en600 - Technology::610 - Medicine & healtharticle10.7892/boris.1201702995035110.1158/1078-0432.CCR-17-3588